SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

JAMA Netw Open. 2026;9(1):e2555843.

National Pilot Program for Antimicrobial Stewardship in the Republic of Korea.

, , , , , , , , , , , , ,

제1저자 이현주,문송미 · 교신저자 김홍빈

소속 (7)
  1. Department of Pediatrics, Division of Infectious Diseases, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  2. Antimicrobial Stewardship Team, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  3. Department of Internal Medicine, Division of Infectious Diseases, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  4. Department of Pharmacy, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  5. Department of Internal Medicine, Division of Infectious Diseases, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
  6. Department of Internal Medicine, Division of Infectious Diseases, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  7. Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.

Abstract

IMPORTANCE Antimicrobial resistance (AMR) poses an urgent global health challenge, undermining treatment efficacy and threatening patient safety. Antimicrobial stewardship (AMS) programs are recognized as essential interventions to optimize antibiotic use, but implementation has often been fragmented and underresourced. The Republic of Korea (ROK), facing high antibiotic consumption and increasing multidrug resistance, launched a national pilot program for AMS as part of its Second National Action Plan on AMR (2021-2025). This program represents the first government-coordinated effort to establish a standardized framework for hospital-based stewardship nationwide.

OBSERVATIONS The pilot program, initiated in November 2024, was developed by the Korea Disease Control and Prevention Agency with academic and clinical partners. It set explicit eligibility criteria, requiring hospitals with at least 300 beds to form multidisciplinary AMS teams with minimum physician and pharmacist staffing. Core program components include leadership commitment, workforce development, guideline implementation, real-time audit and feedback, surveillance, reporting, and education. Institutions undergo annual evaluation based on both foundational and advanced criteria, with operational funding linked to performance grades. Depending on size and evaluation outcomes, hospitals may receive financial support from the government annually. Early implementation highlights both progress and challenges. The program has enabled the establishment of dedicated AMS teams, integration of stewardship into hospital governance, and initiation of national monitoring systems. However, persistent workforce shortages, uneven institutional readiness, limited awareness of AMS among clinicians and the public, and disparities between tertiary and smaller hospitals pose significant barriers. Sustained progress will require workforce expansion, awareness-building, stable long-term financing, and integration of stewardship into broader quality and safety frameworks.

CONCLUSIONS AND RELEVANCE The ROK's national AMS pilot illustrates how government-led policy, financing, and accountability mechanisms can motivate large-scale stewardship implementation. The initiative provides a replicable model for embedding stewardship into health systems while aligning public health priorities with clinical practice. Lessons from the Korean experience are relevant for countries seeking to strengthen national AMR strategies, particularly in resource-limited settings. By institutionalizing stewardship at the policy level, the program offers critical insights for sustaining progress against AMR and advancing global health security.

그 밖의 정보
출판 형태
Journal Article, Research Support, Non-U.S. Gov't
저널
JAMA network open · eISSN 2574-3805
전자 출판
2026-01-02
MeSH
Antimicrobial Stewardship* / organization & administration / methods · Humans · Republic of Korea · Pilot Projects · Anti-Bacterial Agents* / therapeutic use · Program Evaluation
Substances
Anti-Bacterial Agents